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Abstract
Introduction: Tumors are characterized by alterations in the epithelial and stromal compartments, which both
contribute to tumor promotion. However, where, when, and how the tumor stroma develops is still poorly
understood. We previously demonstrated that DNA damage or telomere malfunction induces an activin
A-dependent epithelial stress response that activates cell-intrinsic and cell-extrinsic consequences in mortal,
nontumorigenic human mammary epithelial cells (HMECs and vHMECs). Here we show that this epithelial stress
response also induces protumorigenic phenotypes in neighboring primary fibroblasts, recapitulating many of the
characteristics associated with formation of the tumor stroma (for example, desmoplasia).
Methods: The contribution of extrinsic and intrinsic DNA damage to acquisition of desmoplastic phenotypes was
investigated in primary human mammary fibroblasts (HMFs) co-cultured with vHMECs with telomere malfunction
(TRF2-vHMEC) or in HMFs directly treated with DNA-damaging agents, respectively. Fibroblast reprogramming was
assessed by monitoring increases in levels of selected protumorigenic molecules with quantitative polymerase
chain reaction, enzyme-linked immunosorbent assay, and immunocytochemistry. Dependence of the induced
phenotypes on activin A was evaluated by addition of exogenous activin A or activin A silencing. In vitro findings
were validated in vivo, in preinvasive ductal carcinoma in situ (DCIS) lesions by using immunohistochemistry and
telomere-specific fluorescent in situ hybridization.
Results: HMFs either cocultured with TRF2-vHMEC or directly exposed to exogenous activin A or PGE2 show
increased expression of cytokines and growth factors, deposition of extracellular matrix (ECM) proteins, and a shift
toward aerobic glycolysis. In turn, these “activated” fibroblasts secrete factors that promote epithelial cell motility.
Interestingly, cell-intrinsic DNA damage in HMFs induces some, but not all, of the molecules induced as a
consequence of cell-extrinsic DNA damage. The response to cell-extrinsic DNA damage characterized in vitro is
recapitulated in vivo in DCIS lesions, which exhibit telomere loss, heightened DNA damage response, and increased
activin A and cyclooxygenase-2 expression. These lesions are surrounded by a stroma characterized by increased
expression of a smooth muscle actin and endothelial and immune cell infiltration.
Conclusions: Thus, synergy between stromal and epithelial interactions, even at the initiating stages of
carcinogenesis, appears necessary for the acquisition of malignancy and provides novel insights into where, when,
and how the tumor stroma develops, allowing new therapeutic strategies.
Introduction
Cellular responses to stress are complex and vary, depend-
ing on the cell type, the extent and type of DNA damage
or stress, and the surrounding environment and temporal
considerations. Stress can activate a variety of cell-intrinsic
processes, including autophagy, the unfolded protein
response, and the DNA damage response (DDR), as well
as more irreversible phenotypes, such as apoptosis or
senescence. Cell-intrinsic consequences of cellular stress
often require the initial activation of the DDR through
insults including: DNA damage, telomere malfunction,
and hypoxic stress [1,2]. The DDR facilitates DNA repair
by recruiting and activating DNA-repair proteins in an
attempt to maintain genomic integrity. Additionally, the
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DDR activates p53 and Rb pathway-dependent barriers to
malignancy through the induction of cell-cycle arrest,
apoptosis, or senescence [1,3]. Compromising these bar-
riers can lead to genomic instability and the acquisition of
tumorigenic phenotypes [3-7]. However, cellular-stress
responses are also associated with cell-extrinsic pheno-
types [5,8,9].
We recently showed that the consequences of DDR in
mortal, nontumorigenic human mammary epithelial cells
can also be cell extrinsic. These responses are not confined
to the initial cell that is stressed, but can also be trans-
mitted to adjacent (nondamaged) epithelial cells through
paracrine secretion of stress-induced factors (for example,
an activin A-dependent induction of cyclooxygenase 2
(COX-2)) [5]. In the present study, we investigated
whether activating DDR in primary human mammary
epithelial cells (derived from disease-free tissues), could
have cell-extrinsic consequences, resulting in induction of
genes associated with protumorigenic phenotypes in adja-
cent fibroblasts in vitro.
It is now well recognized that stromal cells within and
surrounding pathologic lesions are not simply passive
structural components, but also actively contribute to
malignant phenotypes through elevated expression of
cytokines and growth factors [10-15]. They exert their
effects through increased deposition and remodeling of
the ECM, reprogramming of metabolism, local alteration
of immune function, and increased vascularization. Col-
lectively, these alterations are known as desmoplasia.
Carcinoma-associated fibroblasts (CAFs) are among the
predominant cell types in the tumor stroma and contri-
bute to most of the phenotypes described earlier
[10,13,16,17]. As expected from these in vitro pheno-
types, CAFs promote tumorigenesis in animal models of
cancer [11,12]. Where, when, and how CAFs come to
acquire these properties is under intensive study
[10,13-15].
Recent studies suggest that multiple secretory pathways
may participate in the development of a protumorigenic
stroma [8,9]. In this study, we show that, in addition to
reprogramming adjacent epithelial cells, stress-elicited fac-
tors from epithelial cells can also reprogram adjacent stro-
mal cells. Additionally, we show that cell-intrinsic DNA
damage in human mammary fibroblasts (HMFs) also
results in an induction of activin A and an upregulation of
genes associated with a tumor stromal program similar,
but not identical, to the program elicited by cell-extrinsic
signaling. In vivo, we demonstrated that preinvasive lesions
(ductal carcinoma in situ, DCIS) exhibiting a DDR (shorter
telomeres and gH2AX foci) are associated with high acti-
vin A and a stromal signature consistent with protumori-
genic phenotypes. Collectively, these data suggest that
DNA damage (telomere malfunction) in nonmalignant
epithelial cells has cell-extrinsic consequences for
neighboring epithelial and stromal cells and implies that
the generation of protumorigenic stromal phenotypes can
occur early in tumorigenesis. These studies provide novel
targets for the prevention of preinvasive lesions.
Materials and methods
Cell culture and induction of DDR
Monocultures
Human mammary fibroblasts (HMFs) were isolated from
disease-free tissues obtained from six individuals: RM9,
RM15, RM21, RM111, RM124, and RM156. HMFs are
primary cells with a finite proliferative capacity, and, given
the number of end points studied, the same HMFs could
not be used for all experiments. However, to ascertain the
relevance of the described phenotypes and to account for
potential interindividual variations, all experiments were
carried out with three independent HMFs obtained from
our collection of six individuals listed earlier, unless other-
wise stated. As previously described, HMFs were isolated
from tissues by using differential centrifugation, filtration,
and media selection (RPMI-1640 + 10% fetal bovine
serum (FBS)) [11]. Fibroblast identity was confirmed
through monitoring expression of specific markers. Unlike
MCF7 mammary epithelial cells, HMFs expressed fibro-
nectin, but not E-cadherin, consistent with a fibroblast
phenotype (see Additional file 1).
HMFs were incubated for 24 hours in media without
serum before the addition of activin A (Sigma-Aldrich,
St. Louis MO), PGE2 (Cayman Chemicals, Ann Arbor,
MI), or the COX-2 inhibitor, NS398 (Cayman Chemicals,
Ann Arbor, MI), for 48 hours. Etoposide (Sigma-Aldrich,
St. Louis MO), and the DNA-PK inhibitor, NU7026
(Sigma-Aldrich, St. Louis MO), were added to the culture
medium (RPMI + 10% FBS) at the doses and times
shown in the figure legends. The media were removed
before exposure to UVC and immediately replaced.
Human mammary epithelial cells with silenced p16INK4A
via promoter methylation, referred to as variant human
mammary epithelial cells (vHMECs) [7,18], were isolated
from disease-free tissues obtained from three women:
RM15, RM78, and RM79. vHMECs were propagated in
MEGM, as previously described [19]. All experiments
were performed on proliferating midpassage cell
populations.
Co-cultures
TRF2 and hTERT were overexpressed in vHMECs from
RM78 and RM79, as described previously [5]. Transwell
dishes (Costar, Tewksbury, MA) with a 0.4-μm pore were
used for coculture experiments. In brief, 1.7 × 105 HMFs
from RM15 and RM21 were plated in RPMI + 10% FBS in
the bottom chamber. The following day, cells were placed
in RPMI without serum for 24 hours. These media were
subsequently replaced with MEGM and an equal number
of vHMECs from RM78 and RM79 overexpressing either
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TRF2, hTERT, vector (pWP), or mock infected were plated
onto the top chamber of the transwell dish. The medium
in the top chamber was replaced after 24 hours. HMFs
were harvested 48 hours after addition of vHMECs to the
transwell dish.
Cell-wounding assay
HMFs from RM111 and RM124 were plated in RMPI +
5% FBS and were exposed to exogenous activin A (0.08
μg/ml) or vehicle (dH20) for 48 hours. Conditioned
media were collected from both HMFs, centrifuged
briefly to remove cellular debris, and diluted in MEGM.
RPMI + 5% FBS supplemented with either exogenous
activin A (0.08 μg/ml) or vehicle was treated identically
to the conditioned media. RM15 vHMECs were cultured
in a 2:1 mix of MEGM and one of each of the following
four media: (a) HMF + activin A-conditioned medium,
(b) HMF + vehicle-conditioned medium, (c) RPMI + 5%
FBS + activin A, or (d) RPMI + 5% FBS + vehicle. After
24 hours, confluent monolayers of vHMECs were manu-
ally disrupted with a pipette tip, and the medium was
removed and replaced with MEGM. Duplicate wells for
each condition from both HMFs were imaged immedi-
ately after wounding and every 4 hours for a total of 28
hours. The size of the “wound” in the vHMEC mono-
layers was measured in three locations for each condition
and time point by using the NIS-Elements D 3.2 software
(Nikon).
Quantitative PCR
Total RNA was isolated from cells and cDNA synthesized
by using standard methods. cDNA was subsequently used
for quantitative polymerase chain reaction (Q-PCR) by
using the standard curve method. Primer-probe sets for
each of the genes were obtained from ABI (Table 1). The
expression of GUSB (IDT), an internal control, was used
to normalize for variances in input cDNA. The forward
and reverse primer and Taqman probe sequences for
GUSB were as follows: 5’ CTCATTTGGAATTTTGCC-
GATT 3’, 5’ CCGAGGAAGATCCCCTTTTTA 3’, 5’
FAM-TGAACAGTCACCGACGAGAGTGCTGGTA-
TAM 3’, respectively. Q-PCR was performed on a CFX-96
(Biorad) thermocycler by using the 2x SsoFast Master Mix
(Bio-Rad Laboratories).
ELISA and lactate assays
ELISAs
Activin A, interleukin 6 (IL-6), interleukin 8 (IL-8), and
vascular endothelial growth factor (VEGF) protein levels
were measured by using the Duo-Set ELISA kits (R&D
Systems, Minneapolis MI). Prostaglandin levels were
measured by using the Prostaglandin E2 E1A ELISA Kit
(Cayman Chemicals, Ann Arbor, MI). To prepare condi-
tioned media, HMFs were plated into duplicate wells of
a six-well plate and exposed to each agent or corre-
sponding vehicle controls 24 hours later. Media were
replaced the following day and allowed to condition for
48 hours. Conditioned media were collected, centrifuged
briefly to remove cellular debris, and stored at -80°C in
siliconized tubes.
Lactate
Lactate levels were measured in media that were condi-
tioned for 4 hours. In brief, cells were treated as described
earlier, and media were replaced with media without exo-
genous agents. Lactate levels were measured immediately
after collection by using Lactate Reagent (Trinity Biotech,
Bray, Co Wicklow, Ireland) and compared with a standard
curve (Sigma-Aldrich, St. Louis, MO). Expression of each
molecule was measured in duplicate assays.
Immunocytochemistry
The levels of fibronectin and a-smooth muscle actin
(aSMA) protein were evaluated in HMFs obtained from
RM9, RM15, and RM111. Cells were plated on glass cov-
erslips, grown to confluence, and incubated in media
without serum for 24 hours before treatment with activin
Table 1 Quantitative PCR probes sets
Gene name Gene abbreviation ABI catalog
Activin A (inhibin bA) INHIB A Hs00170103_m1
Prostaglandin-endoperoxide synthase 2 COX-2 Hs00153133_m1
Tenascin C TenC Hs01115664_m1
Fibronectin 1 FN1 Hs00365052_m1
Collagen, type I, a 1 COL1A1 Hs00164004_m1
Hypoxia-inducible factor 1 a HIF1a Hs00153153_m1
Lactate dehydrogenase A LDHA Hs00855332_g1
Interleukin 6 IL-6 Hs00985639_m1
Interleukin 8 IL-8 Hs01567913_g1
Vascular endothelial growth factor A VEGF Hs00173626_m1
Signal transducer and activator of transcription 3 STAT3 Hs01047580_m1
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A for 48 hours. Cells were subsequently washed twice in
PBS and then fixed in 4% paraformaldehyde for 20 min-
utes at room temperature, followed by a graded methanol
series. Coverslips were exposed to primary antibodies
against fibronectin (1:100, BD Biosciences, San Jose, CA)
and aSMA (1:50, Dako, Carpentaria, CA) overnight at
4°C and visualized with secondary antibodies labeled with
FITC. Nuclei were counterstained with 4’-6-diamidino-2-
phenylindole (DAPI). Tissues were imaged by using a
Zeiss LSM 510 confocal microscope with a 20× objective.
Tissue samples
The 16 cases of nonrecurrent DCIS evaluated in this study
were surgically resected at the University of California San
Francisco Medical Center from 2008 to 2009. Women
treated with neoadjuvant therapy were not included in the
study. Clinical and pathologic information was obtained
from patients’ medical records and pathology reports
(Table 2). DCIS lesions were primarily estrogen- and pro-
gesterone-receptor positive and grade 2 or 3.
All tissues used in this work were accrued with
informed patient consent and studied under institutional
protocols 10-00329, 10-01272, and 10-02471, as
approved by the Human Research Protection Program
Committee on Human Research at the University of
California, San Francisco.
Tissue preparation and immunohistochemistry
Serial 5-μm sections were cut from paraffin-embedded tis-
sue blocks. One section was stained with hematoxylin and
eosin (H&E). Immunohistochemistry was performed on
adjacent serial tissue sections by using standard protocols.
Microwave antigen retrieval in citrate buffer was used for
activin A, gH2AX, and CD31. Antigen retrieval was per-
formed in EDTA for COX-2 and in citrate buffer for
aSMA, in both cases for 60 minutes in an 80°C water bath.
The DCIS lesions were stained for activin A (Sigma-
Aldrich, 1:120, St. Louis, MO), gH2AX (Upstate Biotech-
nology Lake Placid, NY, 1:150), COX-2 (Dako, Carpen-
taria, CA, 1:300), CD31 (Dako, Carpentaria, CA, 1:20),
and aSMA (Dako,Carpentaria, CA, 1:6,400). Slides were
scanned at 20× magnification by using an Aperio Scan-
Scope Digital Slide Scanner (Aperio Technologies, Inc.,
Vista, CA). A minimum of five regions was chosen for
qualitative assessment. Evaluation of activin A, gH2AX,
COX-2, CD31, and aSMA staining intensity or the pro-
portion of immune cell infiltrate (in H&E slides) was
performed in a blinded fashion comparing the same
regions. Staining intensity was scored as low to absent
(low) or moderate to strong (high).
Telomere-FISH
Telomere content was assessed by using telomere-speci-
fic FISH, as previously described [20]. In brief, slides
were deparaffinized and rehydrated through a graded
alcohol series, washed, and then steamed for 25 minutes.
Genomic DNA was denatured for 2 minutes at 84°C.
Two PNA probes, one specific for telomeres (Cy3-
labeled, red) and one specific for centromeres (FITC-
labeled, green), were hybridized to the tissues for
2 hours at room temperature. Slides were washed twice
in 70% formamide, twice in PBS with 0.05% Tween-20,
and thoroughly rinsed in deionized water before coun-
terstaining the nuclei with DAPI. Tissues were air-dried
and mounted with Prolong antifade reagent (Invitrogen,
Grand Island, NY).
Tissues were imaged by using a Zeiss LSM 510 confo-
cal microscope with a 63× objective. Serial slides,
stained with H&E, were used to guide identification of
the DCIS lesions. The absence of centromere signal was
used to exclude regions of tissue or slides (three speci-
mens) with poor fixation and inadequate PNA hybridi-
zation. Telomere lengths were qualitatively scored by
visual assessment of two cellular compartments, DCIS
epithelial cells and adjacent stromal cells, as previously
described [20]. Lesions in which telomere signals were
similar to or brighter than the adjacent stroma were
scored as high. Lesions in which telomere signals were
absent or less than the adjacent stroma were scored as
low.
Statistical methods
Two-sided t tests assuming unequal variance were used to
test the relations between expression of each of several
genes (activin A, COX-2, HIF1a, VEGF, IL-6, IL-8, tenas-
cin C, collagen 1A1, and fibronectin) or proteins (activin
A, IL-6, IL-8, and VEGF), prostaglandin or lactate levels in
HMFs in co-culture, or exposed to activin A, PGE2,
NS398, or DNA-damaging agents (etoposide, NU7026, or
UVC). Changes in the expression for each gene or protein
are shown relative to their respective control in each fig-
ure. Error bars represent the standard error of the mean,
and statistical significance (P ≤ 0.05) is denoted with an
asterisk. A two-tailed Fisher Exact Test was used to evalu-
ate the relation between staining intensity (high or low)
for activin A and telomere FISH, gH2AX, COX-2, CD31,
aSMA, or immune infiltrate. The Jmp 9.0 statistical pack-
age (SAS Institute) was used for all analyses.
Results
Activation of a stress response in epithelial cells repro-
grams adjacent fibroblasts to produce proteins asso-
ciated with desmoplasia
We demonstrated that telomere malfunction in mor-
tal, nontumorigenic human mammary epithelial cells,
with a compromised p16/Rb pathway (vHMEC), results
in sustained induction of activin A [5]. Acting in a cell-
extrinsic fashion, activin A induces cyclooxygenase-2
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Table 2 Patient and tumor characteristics of ductal carcinoma in situ (DCIS) cohort
ID Menopausal statusa DCIS grade ER status PR status Activin A scorec Telo-FISHd gH2AX score COX-2 score- aSMA score CD31 score Immune infiltrate scoree
96 Post 3 + + Low High Low Low Low Low Low
52 Pre/peri 2 + + Low High Low Low Low Low Low
13 Post 2 + + Low High Low Low Low High Low
19 Post 3 - - Low High Low Low High Low Low
50 Pre/peri 1 + + Low High High Low Low Low Low
10 Pre/peri 2 + + Low Low Low Low Low Low Low
69 Post 3 + + Low ND Low Low Low Low High
28 Pre/peri 3 + Unkb Low High High High Low High High
3 Pre/peri 3 + + High High High Low High High High
63 Post 3 - - High ND High High Low High High
47 Post 2 + + High ND High High High High High
84 Post 3 Unkb Unk High Low High High High Low High
15 Pre/peri 3 + + High Low High High High High High
12 Post 3 - - High Low High High High High High
66 Pre/peri 2 + + High Low High High High High High
9 Post 3 + + High Low High High High High High
Sumf Post = 8
Pre/peri = 7
G3 = 10
G2 = 5
G1 = 1
Pos = 12
Neg = 3
Unk = 1
Pos = 11
Neg = 3
Unk = 2
High = 8
Low = 8
High = 7
Low = 6
ND = 3
High = 10
Low = 6
High = 8
Low = 7
High = 8
Low = 8
High = 9
Low = 7
High = 10
Low = 6
aPre- or perimenopausal status (pre/peri) or postmenopausal (post) status was self-reported. bUnknown result (Unk). cProtein expression (activin A, gH2AX, COX-2, aSMA, and CD31) was stratified into two groups, as
described in Methods. dTelomere-specific fluorescence in situ hybridization (Telo-FISH) intensity was stratified into two groups, as described in Methods. Cases in which telomere intensity could not be determined
are shown (ND). eDegree of immune cell infiltrate was evaluated on H&E slides and stratified into two groups, as described in Methods. fSummary of cohort showing the number of cases in each category (ethnicity,
mean age at diagnosis, menopausal status, DCIS grade, ER and PR status, Activin A, gH2AX, COX-2, aSMA, and CD31 protein expression and immune infiltration).
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(COX-2) and its enzymatic byproducts, primarily pro-
staglandin E2 (PGE2), in adjacent epithelial cells, and
activates protumorigenic epithelial phenotypes. To
appreciate fully the impact of this novel stress response,
we investigated whether mammary epithelial cells
(vHMECs) with telomere malfunction, resulting in the
production of activin A and PGE2, could induce pheno-
types associated with desmoplasia in human mammary
fibroblasts (HMFs).
To this end, we co-cultured HMFs with vHMECs over-
expressing the telomere-binding protein TRF2 (TRF2-
vHMEC) or vector control (pWP-vHMEC). We previously
showed that TRF2 overexpression leads to telomere mal-
function and triggers a double-strand DDR [5]. Three hall-
marks of desmoplasia were assessed in the fibroblasts. We
found an increased expression of ECM proteins (for exam-
ple, fibronectin (FN1), collagen 1A1 (Col1A1), and tenascin
C (TenC); Figure 1A, left panel), elevated levels of selected
cytokines (for example, proinflammatory interleukins IL-8
and IL-6 and proangiogenic vascular endothelial growth
factor (VEGF); Figure 1B, left panel), and a switch to aero-
bic glycolysis [21], reflected by the induction of the tran-
scription factor hypoxia-induced factor 1-alpha (HIF1a;
Figure 1C, left panel) in HMFs co-cultured with TRF2-
vHMECs. Similar to our previous findings in epithelial
cells, reprogrammed HMFs exhibited an activation of the
activin A pathway, as documented by increases in activin
A and COX-2 transcript levels in HMFs co-cultured with
TRF2-vHMEC (Figure 1D, left panel).
Having characterized the protumorigenic effects result-
ing from the overexpression of TRF2 in vHMECs, we
investigated whether overexpression of the catalytic subu-
nit of telomerase hTERT in vHMECs (hTERT-vHMEC)
would have opposing effects for each of the documented
phenotypes. In contrast to TRF2, hTERT maintains telo-
mere function, represses the double-strand DDR, and
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Figure 1 Activation of a stress response in epithelial cells reprograms adjacent fibroblasts. RM15 or RM21 human mammary fibroblasts
(HMFs) were cocultured with RM78 or RM79 vHMECs for 24 hours in MEGM. vHMECs overexpressed either TRF2, hTERT, or pWP (vector control),
or expressed a short hairpin for activin A (sh Activin A) or for luciferase (sh control). In all figures, error bars represent SEM, and asterisks denote
statistical significance (P ≤ 0.05) compared with appropriate control. Protein levels were measured with ELISA (duplicates), and mRNA levels were
measured with Q-PCR (triplicate) and compared with appropriate controls (either vector or short hairpin). The relative levels of (A) fibronectin
(FN1), collagen 1A1 (Col1a1), tenascin C (TenC), (B) IL-8, IL-6, VEGF, (C) HIF1a, (D) activin A, and COX-2 mRNAs compared with either vector or
short-hairpin controls for four HMF-vHMEC combinations are shown. In one instance (right side, panel A) only three HMF-vHMEC combinations
were used. #, statistical significance (P ≤ 0.05) compared with sh-control for this particular sample set.
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decreases activin A expression in vHMECs [5]. As
expected, many genes induced in HMFs co-cultured with
TRF2-vHMECs (tenascin C, IL-8 and IL-6, HIF1a, and
COX-2) were repressed in HMFs co-cultured with
hTERT-vHMECs (Figure 1A through 1D, left panels).
Activin A is necessary and sufficient to induce
protumorigenic phenotypes in HMFs
To establish causality between the induction of activin A
in epithelial cells and the production of desmoplasia-
associated proteins in reprogrammed HMFs, we deter-
mined whether activin A was necessary for the induction
of these genes by silencing its expression in vHMECs
with a short-hairpin RNA to activin A (sh Activin A-
vHMEC), as described [5]. HMF cells cocultured with
vHMECs expressing a short hairpin to luciferase (sh con-
trol-vHMECs) were used as a baseline. Repression of
activin A in vHMECs resulted in significant decreases in
each of the previously measured end points, except col-
lagen 1a1, which showed a nonstatistically significant
decrease (Figure 1A through 1D, right panels). Thus, tel-
omere malfunction in vHMECs induces many of the
molecules associated with desmoplasia in neighboring
fibroblasts via paracrine signaling. Additionally, we
showed that activin A expression in vHMECs is neces-
sary for the induction of these genes in HMFs.
To investigate whether exogenous activin A was suffi-
cient to induce genes associated with desmoplasia in
HMFs, we exposed HMFs to exogenous activin A for 48
hours. Two doses were tested to determine whether the
response to activin A was dose dependent: one similar to
the absolute amount induced by DNA damage (0.08 μg/
ml), and the other, a fourfold greater dose (0.32 μg/ml).
As observed in HMFs cocultured with TRF2-vHMECs,
HMFs directly exposed to exogenous activin A exhibited
an increase in the four groups of genes described in Fig-
ure 1. Increased fibronectin, collagen 1A1, and tenascin C
mRNA levels (Figure 2A, left panel) and an accumulation
of fibronectin and a-smooth muscle actin (aSMA) pro-
teins (Figure 2A, right panel) were observed for stromal
proteins. HMFs also displayed an increase in expression
of selected cytokines, such as IL-6 and VEGF proteins
(3.6- and 2.8-fold, respectively; Figure 2B, left panel) and
their mutual downstream effector, signal transducer and
activator of transcription 3 (STAT3; Figure 2B, right
panel). Interestingly, although IL-8 protein and mRNA
levels were increased by direct exposure to DNA damage
(see later) and coculture with TRF2-vHMECs, respec-
tively (Figure 1B, left panel), they were not changed on
exposure to exogenous activin A (Figure 2B, left panel).
HMFs exposed to activin A showed a switch to aerobic
glycolysis with an increase in HIF1a (1.8-fold; Figure 2C,
left panel) and one of its transcriptional targets known to
drive the switch to aerobic glycolysis, lactate
dehydrogenase A (LDHA; Figure 2C, center panel). The
concomitant increase in lactate (Figure 2C, right panel),
the product of LDHA, demonstrates the functional rele-
vance of this finding.
Finally, consistent with our previous studies in vHMECs,
activin A induced its own expression (Figure 2D, left
panel), as well as that of COX-2 (Figure 2D, center panel)
and the subsequent production of PGE2 in HMFs (Figure
2D, right panel).
We also evaluated the response of HMFs as a function
of activin A dose for a subset of the genes described ear-
lier. As shown in Additional file 2, activin A and HIF1a
mRNAs were induced by as little as 0.005 μg/ml of exo-
genous activin A in HMFs. Tenascin C and IL-6 levels
were increased in response to as little as 0.0012 μg/ml of
activin A. Taken together, these observations showed that
HMFs exhibited a dose-dependent response when directly
exposed to activin A and that even very low concentra-
tions of activin A could induce a desmoplastic-like
signature.
COX-2 activity is necessary and sufficient to induce
protumorigenic phenotypes in HMFs
Is COX-2, acting downstream of activin A, responsible for
reprogramming HMFs? One would predict that this is the
case, because prostaglandins, which are products of COX-
2 activity, can upregulate IL-8, IL-6, VEGF, and HIF1a in
tumor epithelial cells [22,23]. To determine whether
COX-2 activity was sufficient to trigger protumorigenic
phenotypes in fibroblasts, we treated HMFs with two
doses of PGE2, 3 and 30 ng/ml, similar to those measured
in vHMECs with elevated COX-2 expression in response
to telomere malfunction [5]. In HMFs treated with the
high dose of PGE2, the levels of fibronectin remained
unchanged, collagen 1A1 was moderately induced, and
tenascin C expression increased, although this increase
was not statistically significant (Figure 3A). HMFs also dis-
played increases in IL-8 (1.6-fold), IL-6 (4.2-fold), and
VEGF (2.3-fold) proteins (Figure 3B) and HIF1a (1.7-fold)
mRNA (Figure 3C) and modest increases in activin A pro-
tein and COX-2 mRNA (Figure 3D).
To determine whether COX-2 activity was necessary for
the induction of these genes, we treated HMFs with 10
μM COX-2 inhibitor NS398, a dose that ablated PGE2
levels by 70% (data not shown). Treatment of HMFs with
NS398 resulted in a 25% and 30% decrease in IL-8 and IL-
6 protein levels, respectively (Figure 3B), but had no effect
on fibronectin, collagen 1A1, tenascin C, VEGF, HIF1a, or
activin A (Figure 3A through 3D, respectively). COX-2
mRNA was repressed by NS398 and induced by PGE2,
suggesting that COX-2 activity participated in a positive-
feedback loop to drive its own expression in HMFs (Figure
3D). In summary, PGE2 induced collagen 1A1, IL-6, VEGF,
and HIF1a. COX-2 activity was necessary only for the
Fordyce et al. Breast Cancer Research 2012, 14:R155
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Figure 2 Activin A is sufficient to induce genes and phenotypes consistent with desmoplasia in human mammary fibroblasts (HMFs).
RM9, RM15, RM111, or RM124 HMF was exposed to exogenous activin A at the indicated doses for 48 hours. mRNA levels were assessed with
Q-PCR. Cytokines, growth factors, and PGE2 were measured with enzyme-linked immunosorbent assay (ELISA). Lactate levels were evaluated with
colorimetric assay. Mean expression changes for three individuals were analyzed in duplicate and expressed relative to control, (A) fibronectin
(FN1), collagen 1A1 (Col1a1), and tenascin C (TenC) mRNA levels (left). Immunocytochemical detection of fibronectin or a-smooth muscle actin
(aSMA, green) in RM156 HMF; nuclei in blue (right). (B) IL-8, IL-6, VEGF proteins (left) and STAT3 mRNA (right). (C) HIF1a mRNA (left), LDHA
mRNA (middle), and lactate (right). (D) Activin A mRNA and protein (left), COX-2 mRNA (middle), and PGE2 levels (right).
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induction of IL-8 and IL-6. Collectively, these data suggest
that COX-2 mediates the induction of some, but not all, of
the molecules induced by activin A in HMFs and that
these secreted factors may work in concert to elicit an
extensive stromal reaction to epithelial stress signals.
Conditioned media from HMFs exposed to activin A
enhance motility of epithelial cells
Having shown that exogenous activin A is sufficient to
induce expression of a variety of signaling molecules in
reprogrammed HMFs, we investigated whether secretion
of some of these molecules could, in turn, affect epithelial
cell phenotypes. Based on previous reports showing that
activin A and prostaglandins promote cell motility
[22,24-26], we assessed the motility of vHMECs by using
a cell-wounding assay. Cells were exposed to media
alone, media with activin A (0.08 μg/ml), or conditioned
media from HMFs exposed (or not) to activin A
(0.08 μg/ml). The vHMECs exposed to conditioned med-
ium from HMFs treated with exogenous activin A were
more motile than were vHMECs exposed to any of the
three other media described earlier (Figure 4). These data
demonstrated that HMFs exposed to activin A secreted
factor(s) that induced a motility phenotype in vHMECs.
Collectively, these data showed that a stress response in
vHMECs (induced by telomere malfunction), and the
resulting production of activin A, generated an activated
(desmoplastic) stroma. In turn, the activated stroma,
through production of additional secreted factors, elicited a
protumorigenic epithelial phenotype (increased cell moti-
lity). Activation of epithelial motility in these cells could
propagate the seeding and spreading of a protumorigenic
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Figure 3 COX-2 activity is sufficient to induce phenotypes consistent with desmoplasia. RM9, RM15, RM111, or RM124 human mammary
fibroblasts (HMFs) were exposed to exogenous PGE2 or the COX-2 inhibitor, NS398, for 48 hours. mRNA levels for fibronectin (FN1), collagen 1A1
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field of tissue. Importantly, this bidirectional cellular com-
munication occurs in primary (nontransformed) cells,
suggesting that alterations in epithelium-fibroblast commu-
nication may occur early in tumorigenesis.
Intrinsic DNA damage in HMFs elicits a subset of
phenotypes associated with signaling from extrinsic
DNA damage
We previously showed that double-strand DNA damage
in epithelial cells results in an activin A-dependent
induction of COX-2 [5]. Because exposure to DNA-
damaging agents in vivo would affect not only epithelial
cells, but also the entire tissue, we sought to determine
whether activin A and COX-2 were induced in HMFs in
response to cell-intrinsic DNA damage (Figure 5A
through 5H). HMFs were exposed to etoposide (to
induce double-strand DNA damage), NU7026 (a DNA-
PK inhibitor that mimics telomere malfunction), and
UVC (to induce single-strand DNA damage) by using the
same conditions that induced activin A and COX-2 in
vHMECs [5]. Interestingly, in contrast to the coculture
experiments, cell-intrinsic DNA damage in HMFs
repressed the expression of fibronectin, tenascin C, and
HIF1a (Figure 5A, B, and 5F, respectively), three genes
associated with desmoplasia that were induced by exo-
genous activin A (Figure 2A and 2C). Similar to our
observations of fibroblasts cocultured with epithelial cells
expressing a DDR, IL-8, IL-6, and VEGF proteins were
induced in HMFs directly exposed to DNA-damaging
agents (Figure 5C through 5E, respectively). Consistent
with our previous findings in vHMECs [5], activin A and
COX-2 were increased in HMFs exposed to all three
agents, but to different extents and with different kinetics
(Figure 5G and 5H).
Although HMFs exhibited very different toxicities to
etoposide or NU7026 (4.2-fold versus 1.8-fold cell death
after 48 hours; see Additional file 3), both exposures
resulted in similar expression changes for most molecules
investigated. Furthermore, treatment of HMFs with lower
doses of etoposide (10 μM) and UVC (60 J/m2), both of
which induced a similar degree of cell death as NU7026
(0.05 μM, Additional file 3), also induced the secreted fac-
tors IL-8, IL-6, and VEGF, activin A, and COX-2 (see
Additional file 4B, C, D, F, and 4G, respectively). Likewise,
tenascin C and HIF1a were repressed, even when cell
death was low in HMFs treated with etoposide or UVC
(see Additional file 4A and 4E). The findings that doses of
stress agents that elicited minimal cell death still induced
the expression of activin A, COX-2, and selected molecules
associated with desmoplasia demonstrated that DNA
damage per se, rather than cell death, accounted for these
phenotypes.
HMFs are less responsive to DNA damage-dependent
induction of activin A than are vHMECs
Because activin A and COX-2 were induced in both
epithelial cells [5] and fibroblasts (Figure 5) in response
to DNA damage, we compared the degree and timing of
induction of these molecules in vHMECs and HMFs iso-
lated from the same individual. HMFs had higher basal
levels of activin A (2.7-fold) and COX-2 (2.6-fold)
mRNAs than did vHMECs (Figure 6A). However, the
fold induction of activin A was much less extensive in
HMFs than in vHMECs exposed to damage (Figure 6B).
In summary, the responses of vHMECs and HMFs to
cell-intrinsic DNA damage vary in the magnitude of the
induction of activin A and COX-2. Moreover, our obser-
vations suggest that the pathways induced in HMFs in
response to cell-intrinsic DNA damage are not identical
to those induced in response to exogenous activin A.
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More generally, these data imply that direct DNA damage
to a tissue results in an accumulation of unique cell type-
specific intrinsic and extrinsic responses (Figure 6C).
Expression of activin A in DCIS is associated with reduced
telomeres and desmoplastic-like phenotypes
Having characterized a complex stress response or stress-
elicited extrinsic phenotype (SEEP) in epithelial cells and
neighboring fibroblasts in vitro, we sought to validate the
relevance of our findings in vivo. Our previous work
showed that loss of telomere DNA is associated with a tel-
omere-malfunction signature characterized by higher
gH2AX (a DNA-damage marker), activin A, and COX-2
expression, in DCIS epithelia [5]. We used a pilot cohort
of 16 DCIS cases (Table 2) to determine whether this telo-
mere-malfunction signature was associated with an upre-
gulation of phenotypes associated with desmoplasia. We
assessed angiogenesis (CD31), the acquisition of “acti-
vated” fibroblasts (aSMA), and immune cell infiltration
(visual inspection) adjacent to DCIS lesions. Telomere
length was assessed with telomere-FISH in the 13 cases
that were of sufficient quality.
Consistent with our previous study, we found that DCIS
lesions with high activin A expression (Figure 7B) exhib-
ited reduced telomere signal (P = 0.03) and higher levels
of gH2AX (P = 0.01) and COX-2 (P = 0.01) when com-
pared with lesions with low activin A (Figure 7A). Next,
we interrogated whether activin A expression levels in a
DCIS lesion could reflect the characteristics of adjacent
stromal cells in vivo. DCIS lesions with high levels of acti-
vin A (Figure 7B) were associated with an increase in “acti-
vated” fibroblasts, as reflected by the increase in
expression of aSMA (P = 0.01), angiogenesis, as illustrated
by the increased expression of CD31 (P = 0.04), and
immune cell infiltration (P = 0.007) in the adjacent stroma
when compared with lesions with low levels of activin A
(Figure 7A). These in vivo findings of stress-elicited extrin-
sic phenotypes (SEEPs), in the setting of preinvasive can-
cer, validate the conclusions drawn from our in vitro
experiments (that is, high activin A levels in epithelial cells
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Figure 5 Direct DNA damage in human mammary fibroblasts (HMFs) alters the expression of molecules associated with desmoplasia.
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are associated with desmoplastic-like phenotypes in the
adjacent stroma) (Table 3).
Discussion
These studies provide insights into early cell-cell interac-
tions that participate in premalignancy and malignancy.
They demonstrate that cell-intrinsic DNA damage can act
beyond the cell in which the damage originally occurs and
extend the consequences to reprogramming the neighbor-
ing epithelial and stromal cells in a dramatic and clinically
relevant fashion. We previously showed that DNA damage
and telomere malfunction in human mammary epithelial
Figure 7 Activin A in ductal carcinoma in situ is associated with reduced telomeres and desmoplastic-like phenotypes. gH2AX, an
indicator of DNA damage, activin A, COX-2, aSMA, and CD31 protein levels were assessed with immunohistochemistry (IHC) on serial sections of
each DCIS lesion. Telomere signal (red) and centromere signal (green; internal control) in epithelial cells were compared with those in the
adjacent stroma. Nuclei: DAPI (blue). Lesions were divided into two groups based on staining intensity for each protein and relative amounts of
telomere signal (high or low) and of immune infiltrate (from H&E, high or low). (A) Stress-elicited extrinsic phenotype (SEEP) Inactive. Top row:
serial sections of a representative DCIS lesion (10×) with high telomere-FISH signal, low expression of gH2AX, activin A, COX-2, aSMA, and CD31
proteins, and low immune infiltrate. Bottom row: 20× (IHC) or 63×-zoom (telomere-FISH) micrographs of the indicated regions shown in the top-
row insets. (B) SEEP Active. Top row: serial sections of a representative DCIS lesion (10×) with low telomere-FISH signal, high expression of
gH2AX, activin A, COX-2, aSMA, and CD31 proteins and high immune infiltrate. Bottom row: 20× (IHC) or 63×-zoom (telomere-FISH) micrographs
of the indicated regions shown in the top-row insets.
Table 3 High activin A expression in ductal carcinoma in situ (DCIS) is associated with stress-elicited extrinsic
phenotypes
Telomere FISHa gH2AXb COX-2b aSMAb CD31b Immune infiltratec
Low 1 6 6 2 7 1 7 1 6 2 6 2
Activin A High 5 1 0 8 1 7 1 7 1 7 0 8
P value 0.03 0.01 0.01 0.01 0.04 0.01
aTelomere-specific fluorescence in situ hybridization (FISH) was evaluated on serial sections from each lesion. Lesions in which the telomere signals were equal or
of greater intensity than adjacent stroma were scored as high. Lesions in which the telomere signal was less than the adjacent stroma were scored as low.
bProtein levels were evaluated by using immunohistochemistry (IHC) on serial sections from each lesion and scored as absent to low (low) or moderate to high
(high). cImmune infiltrate was evaluated on serial sections of each lesion stained with H&E and scored as absent to low (low) or moderate to high (high). P values
were calculated by using a two-sided Fisher Exact Test.
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cells results in an activin A-dependent induction of COX-
2 [5], causing cell-cycle arrest in non-p16-compromised
epithelial cells and increased proliferation, motility, prosta-
glandin synthesis, and decreased apoptosis in p16-compro-
mised epithelial cells [4,5]. We also established that
secreted activin A can subsequently transmit a similar
upregulation of COX-2 in adjacent epithelial cells that
lack DNA damage or telomere malfunction. Thus, stress
signals can be propagated beyond the cell with the original
insult.
Here we extend our initial observations by documenting
that epithelial cells with DNA damage (telomere malfunc-
tion) can induce activin A and COX-2 in neighboring
HMFs (Figures 1, 6B, 7, and 8). Moreover, activin A, func-
tioning once again in a cell-extrinsic fashion, induces
tumor-promoting phenotypes in HMFs and, presumably,
in endothelial and immune cells. These phenotypes
include altered expression and deposition of ECM proteins
(fibronectin, aSMA collagen 1A1, and tenascin C),
increased expression of several cytokines and growth fac-
tors (IL-8, IL-6, and VEGF), and a shift toward aerobic gly-
colysis (Figures 1 and 2). Furthermore, conditioned media
obtained from HMFs exposed to activin A enhance the
motility of epithelial cells, demonstrating that these epithe-
lia-induced changes in HMFs can, in turn, alter the beha-
vior of surrounding epithelial cells (Figure 4). These
stress-elicited extrinsic phenotypes (SEEPs) document that
early conversations between the epithelium and the
stroma in carcinogenesis are truly bidirectional processes
(Figure 8).
We hypothesize that these observations are critically
relevant for tumor initiation and progression. DNA dou-
ble-strand breaks (DSBs) (and the induction of DDR) are a
common consequence of oncogene activation, replicative
stress, inflammatory reactions, chromosomal breakage,
and hypoxic stress, and also result from radio- and che-
motherapy. Likewise, telomere malfunction occurs in vir-
tually all tumor types, and, in many cases, in preinvasive
lesions such as DCIS [27,28]. In situ hybridization has
demonstrated that telomere malfunction typically occurs
in the epithelial compartment [20,29] and is associated
with poor prognosis and the progression of several malig-
nancies [30-34]. The classic view is that DNA damage
indirectly contributes to tumorigenesis through genomic
instability that results in loss of tumor suppressors and
activation of oncogenes. Our data suggest that these stress
signals, acting in a cell-extrinsic fashion, can also directly
contribute to tumorigenesis via early reprogramming to a
protumorigenic stroma, even before the development of
immortal tumorigenic epithelial cells.
Understanding how these signals contribute to cell-
extrinsic events may provide novel insights critical for the
detection, prevention, and treatment of cancer.
Additionally, our study shows that cellular stress in an
epithelial cell can increase HIF1a levels, aerobic glycolysis,
and lactate production in neighboring fibroblasts through
secretion of activin A, a member of the TGF-b superfam-
ily. The TGF-b pathway has been previously reported to
drive increases in HIF1a, aerobic glycolysis, and lactate
production in fibroblasts [35-37]. The mechanistic findings
described by us are strikingly similar to those reported in
the context of the Reverse Warburg Effect. In this latter
phenotype, tumor epithelial cells induce an increase in
aerobic glycolysis and lactate production in adjacent stro-
mal cells through production of reactive oxygen species
[21,38]. The lactate produced by stromal cells is, in turn,
released in the local microenvironment, where it is used by
tumor epithelial cells, presumably along with other meta-
bolic intermediates, to fuel cell proliferation [14,37,38]. The
novel stress response described by us here, and the Reverse
Warburg Effect, therefore appear to be two programs that
rely heavily on epithelium-fibroblast communication.
In both cases, epithelial cells induce aerobic glycolysis in
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Figure 8 Stress-elicited extrinsic phenotypes (SEEPs). In human
mammary epithelial cells with an intact p16/Rb pathway (HMEC,
green cells), DNA damage (or telomere malfunction) causes cell-
cycle arrest and is self-limiting. In contrast, the same type of
damage in human mammary epithelial cells with a compromised
p16/Rb pathway (vHMEC, red cells) results in the activin A-
dependent induction of COX-2 and continued cell proliferation [5].
Activin A can drive increased COX-2 expression in adjacent
epithelial cells [5] and fibroblasts (tan cells; current work) via
paracrine signaling. Fibroblasts adjacent to epithelial cells with
telomere malfunction, or exposed to activin A or PGE2, upregulate a
number of genes to induce cell-extrinsic phenotypes associated
with a protumorigenic microenvironment, as shown [10,16].
Collectively, these factors can alter the extracellular matrix, induce
angiogenesis, increase immune cell influx, drive cell proliferation,
damage DNA, facilitate the switch to anaerobic metabolism, and
promote cell motility [4,14,17,22,23,26,61-63].
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fibroblasts; such altered fibroblasts can then promote
malignant phenotypes in epithelial cells (that is, motility or
proliferation). These programs may therefore represent key
complementary components of SEEPs.
The consequences of SEEPs may vary, depending on the
cellular components of the tissue subjected to damage.
DNA DSB or telomere malfunction in epithelial cells with
intact p53 and p16 pathways would be contained, because
we showed that overexpression of COX-2 in p16-compe-
tent HMECs activates cell-cycle arrest [5,6]. Likewise, cel-
lular stress intrinsic to breast fibroblasts would also be
relatively constrained because they arrest (data not shown)
or die (see Additional file 3). In contrast, if the initiating
damage occurs within an epithelial cell with a compro-
mised p16 response (vHMEC), the consequences could be
much more widespread. In these cells, overexpression of
COX-2 is a proliferative signal and also causes an autoin-
duction of activin A and COX-2. The resultant secretion
of factors on neighboring epithelial and stromal cells can
be profound and everextending, both by virtue of para-
crine signaling and by the induction of epithelial motility,
which could expand the reprogrammed region. Strikingly,
fibroblasts exposed to exogenous activin A do not arrest
or die and additionally exhibit expression changes (that is,
increased HIF1a, fibronectin, and tenascin C) that are not
observed in fibroblasts with cell-intrinsic DNA damage.
We reported the presence of p16-compromised epithe-
lial cells as expanded foci in healthy breast tissue [4,18].
Cells obtained from these foci have documented overex-
pression of COX-2 and telomere malfunction [4,7].
Premalignant lesions, such as DCIS, are often found in
expanded foci of these cells in vivo [39]. Reaching a critical
threshold of such cells could result in a sustained signaling
that would remodel local tissue components, both epithe-
lial and stromal, to support the synergistic emergence of a
malignant lesion. In contrast, the presence of cells with
intact p16 intermixed with cells that have activated SEEPs
would limit SEEP signaling to a confined area and eventual
extinction.
This view would be consistent with our previous studies
demonstrating that DCISs with a compromised p16/pRB
pathway and overexpression of COX-2 are at high risk for
progressing to invasive cancer [6]. Likewise, DCIS lesions
that exhibit a senescence signal, as indicated by increased
p16 in the absence of proliferation, rarely progress [6].
Finally, in DCIS lesions, higher activin A expression is
associated with telomere loss and increased COX-2
expression in the epithelial compartment, and increased
expression of aSMA (which reflects activation of fibro-
blasts), increased immune cell infiltration, and increased
angiogenesis in the adjacent stroma (Figure 7). These in
vivo findings are consistent with the in vitro observations
summarized earlier and provide a rationale for identifying
biomarkers for risk stratification.
Some of the secreted molecules we describe have been
reported as part of the secretory phenotypes associated
with senescent cells [9,40]. The role of cellular senescence
in malignancy is complex. The induction of senescence in
epithelial cells constitutes a barrier to malignant transfor-
mation [41,42], perhaps through the induction of irreversi-
ble cell-cycle arrest in damaged cells at high risk for
expansion and malignant progression. In keeping with this
view, induction of senescence by DNA damage-inducing
chemotherapy arrests tumor progression [43]. It has also
been argued that factors secreted by senescent cells elicit
deleterious cell nonautonomous effects that alter the tissue
microenvironment [44]. Senescent fibroblasts secrete more
than 40 factors associated with intercellular signaling,
including IL-6 and IL-8, many of which have been impli-
cated in tumor progression [8,45]. This complex pheno-
type, defined as senescence-associated secretory phenotype
(SASP), is not a fixed phenotype but rather a secretory pro-
gram with unique qualitative and quantitative functions
depending on cell type, damage type, extent, and environ-
mental conditions.
Several of the characteristics of SASPs are similar to
those of SEEPs, in that both programs are triggered by
DNA damage and upregulate a core of secretory proteins
that exert protumorigenic phenotypes. However, SASPs
can easily be distinguished from SEEPs. SASPs develop
over several days, occurs only after DNA damage exceeds
a threshold that is associated with irreversible cell-cycle
arrest, and is amplified by the loss of p53 [44]. In contrast,
SEEPs develop within hours, is triggered by levels of DNA
DSBs that are compatible with cell proliferation, and
finally, requires p53 activity [5].
Activin A, a lynchpin of the SEEP program, is a secreted
factor and a member of the TGF-b superfamily. Like
TGF-b, activin A functions in a cell type- and tissue-
dependent fashion [46,47]. Studies evaluating the role of
activin A in breast tumorigenesis have largely focused on
the epithelial compartment, where activin A overexpres-
sion inhibits apoptosis and increases tumor volume in
xenograft models of breast cancer [48]. Activin A is often
upregulated in DCIS and in invasive breast cancer com-
pared with normal breast tissue [49,50]. Higher activin A
expression in various types of tumors with local recur-
rence or metastasis to lymph nodes supports that activin
A may have prognostic significance [51,52] and help to
predict response to neoadjuvant therapy [53].
The findings described here are also consistent with
previous studies showing that activin A signaling plays an
important role outside the epithelium. Activins mediate
epithelial-stromal interactions during mammary gland
branching [54]. High activin A levels in tumors are asso-
ciated with upregulation of genes consistent with a des-
moplastic stroma and progression to metastatic disease
[53]. Secretion of activin A by carcinoma-associated
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fibroblasts (CAFs) enhances tumorigenesis [55]. Activin
A serum levels are elevated in patients with metastatic
breast tumors [56,57]. This demonstrates that exogenous
activin A can induce a wide panel of molecules associated
with protumorigenic phenotypes, and implies that, in
addition to its role in epithelial cells, activin A may be a
potent modulator of stroma structure and function.
The “activation” of fibroblasts mediated by SEEP pro-
vides a novel mechanism for initiation of a protumorigenic
stromal response. CAFs are often the most abundant cell
type within the protumorigenic or desmoplastic stroma,
and logically directly contribute to acquisition of its char-
acteristics [10,11,13]. Fibroblasts with CAF-like pheno-
types have been postulated to derive from (a) resident
fibroblasts, and/or (b) mesenchymal stem cells that have
been progressively altered by exposure to tumor epithelial
cells or their secreted factors [58-60]. In these scenarios,
the generation of a CAF requires interaction with tumor
epithelial cells, and therefore prior acquisition of tumori-
genic phenotypes by the epithelial cell compartment.
Importantly, our studies demonstrate that this conversa-
tion between epithelial and stromal cells occurs before
tumorigenesis because the epithelial cells used in our
study are mortal and nontumorigenic [7].
Conclusions
In summary, we show that DNA damage (telomere mal-
function) in mortal, nontumorigenic epithelial cells
induces tumor-promoting phenotypes in adjacent HMFs
through activin A and COX-2. Acting in a cell-extrinsic
fashion, these molecules drive (a) increased expression
and deposition of ECM proteins, (b) elevated levels of
cytokines and growth factors, and (c) a shift toward
aerobic glycolysis. Importantly, conditioned media from
HMFs exposed to exogenous activin A enhance the
motility of adjacent epithelial cells. Thus, the molecular
conversation between the epithelia and stroma is truly
bidirectional. This work extends our previous study,
showing that activin A and COX-2, induced by DNA
damage in epithelial cells, can alter the behavior of adja-
cent, unaffected epithelia [5]. Collectively, these stress-
elicited extrinsic phenotypes (SEEPs) demonstrate that
DNA damage has cell-extrinsic consequences that lead
to reprogramming of both epithelial and stromal cells
(Figure 8) and provide novel insights into the clinical
implications of these early cell-cell interactions as they
contribute to premalignancy and malignancy.
Additional material
Additional file 1: Characterization of HMFs. Representative HMFs
(derived from three donors) and MCF7 mammary epithelial cells. The top
row shows differential interference contrast (DIC) images of cell
morphology. The cells were immunostained for a fibroblast-specific
marker, fibronectin (middle row), and an epithelium-specific marker, E-
cadherin (bottom row), both in red. Nuclei were visualized by using DAPI
(blue).
Additional file 2: Dose response of HMFs treated with activin A on
selected genes associated with desmoplasia. RM111 HMFs were
grown in the absence of serum for 24 hours and then exposed to
exogenous activin A at the indicated doses for 48 hours. mRNA levels for
each gene were assessed in triplicates with Q-PCR and normalized
relative to GUSB, an internal control.
Additional file 3: Cell viability after treatment with DNA-damaging
agents. RM9, RM15, and RM156 HMFs were treated with etoposide, UVC,
and NU7026 at the indicated doses and times. (A) The mean number of
trypan blue-positive cells (an indicator of cell death) was expressed relative
to untreated controls at each time point. (B) The mean number of total
cells was expressed relative to untreated controls at each time point.
Additional file 4: Low doses of etoposide and UVC alter the
expression of molecules associated with desmoplasia in HMF. RM9,
RM15, and RM156 HMFs were treated with 10 μM etoposide (dashed
line) or 60 J/m2 UVC (solid line). Average values for protein levels
(measured in duplicate) for IL-8 (B), IL-6 (C), VEGF (D), and activin A (F);
mRNA levels (measured in triplicate) for Ten C (A), HIF1a (E), and COX-2
(G) are shown relative to untreated controls at each time point. Data
points shown in red illustrate statistically significant differences.
Abbreviations
CAF: carcinoma-associated fibroblast; Col1A: collagen 1A1; COX-2:
cyclooxygenase 2; DAPI: 4’-6-diamidino-2-phenylindole; DCIS: ductal
carcinoma in situ; DDR: DNA-damage response; DNA-PK: DNA-dependent
protein kinase; DSB: DNA double-strand break; ECM: extracellular matrix;
ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; FISH:
fluorescence in situ hybridization; FITC: fluorescein isothiocyanate; FN1:
fibronectin; γH2AX: gamma-histone 2AX; GUSB: β-glucuronidase; HIF1α:
hypoxia-inducible factor 1α; HMF: human mammary fibroblast; HMEC:
human mammary epithelial cell: intact p16/Rb pathway; hTERT: human
telomerase reverse transcriptase; IL-6: interleukin 6; IL-8: interleukin 8; LDHA:
lactate dehydrogenase A; PGE2: prostaglandin E2; PNA: peptide nucleic acid;
Q-PCR: quantitative polymerase chain reaction; Rb: retinoblastoma protein;
RM: reduction mammoplasty; SASP: senescence-associated secretory
phenotype; SEEP: stress-elicited extrinsic phenotype; αSMA: α-smooth muscle
actin; STAT3: signal transducer and activator of transcription 3; TenC:
tenascin C; TGF-β: transforming growth factor β; TRF2: telomeric repeat-
binding factor 2; UVC: ultraviolet subtype C; VEGF: vascular endothelial
growth factor; vHMEC: variant human mammary epithelial cell: silenced p16
expression.
Acknowledgements
The authors thank Dr. P. Gascard for editorial assistance, Dr. C. Heaphy
(Johns Hopkins University) for technical assistance with telomere-specific
FISH, and Dr. A. Au (University of California, San Francisco), Drs. J. Kim and B.
Hornik (Kaiser Foundation Research Institute), Dr. S. Jeffrey (Stanford
University School of Medicine), and Dr. S. Sukumar (Johns Hopkins University
School of Medicine) for providing breast tissues. This work was supported by
NIH/NCI grants PO1 CA107584, R01 CA097214, U54 CA143803, and California
Breast Cancer Research Program 14OB-0165 to TDT and R01 Research
Supplement for Underrepresented Minorities to CAF.
Author details
1Department of Pathology, University of California, San Francisco, HSW 501,
513 Parnassus Avenue, San Francisco, CA 94143, USA. 2Cancer Biology and
Institute for Biophysical Dynamics, University of Chicago, GCIS W309, 929 E
57th Street, Chicago, IL 60642, USA. 3Department of Surgery, Duke
University, Seeley Mudd Building Room 465, Duke University Medical Center,
Durham, NC 27710, USA.
Authors’ contributions
CAF and TDT developed the experimental design. CAF, KTP, TBF, and RAD
conducted and analyzed the in vitro experiments. ESH provided DCIS
Fordyce et al. Breast Cancer Research 2012, 14:R155
http://breast-cancer-research.com/content/14/6/R155
Page 16 of 18
samples and patient history. JZ performed IHC staining. CAF and KTP
performed telomere-specific FISH and qualitatively assessed the IHC staining
and telomere-specific FISH. CAF, RAD, and TDT wrote the manuscript. All
authors read and approved this manuscript for publication.
Competing interests
The authors have no competing interests to disclose.
Received: 27 June 2012 Revised: 12 October 2012
Accepted: 29 November 2012 Published: 7 December 2012
References
1. Jackson SP, Bartek J: The DNA-damage response in human biology and
disease. Nature 2009, 461:1071-1078.
2. Olcina M, Lecane PS, Hammond EM: Targeting hypoxic cells through the
DNA damage response. Clin Cancer Res 2010, 16:5624-5629.
3. Reinhardt HC, Schumacher B: The p53 network: cellular and systemic
DNA damage responses in aging and cancer. Trends Genet 2012,
28:128-136.
4. Crawford YG, Gauthier ML, Joubel A, Mantei K, Kozakiewicz K, Afshari CA,
Tlsty TD: Histologically normal human mammary epithelia with silenced
p16(INK4a) overexpress COX-2, promoting a premalignant program.
Cancer Cell 2004, 5:263-273.
5. Fordyce C, Fessenden T, Pickering C, Jung J, Singla V, Berman H, Tlsty T:
DNA damage drives an activin a-dependent induction of
cyclooxygenase-2 in premalignant cells and lesions. Cancer Prev Res
(Phila) 2010, 3:190-201.
6. Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew K, Moore D,
Rabban J, Chen YY, Kerlikowske K, Tlsty TD: Abrogated response to cellular
stress identifies DCIS associated with subsequent tumor events and
defines basal-like breast tumors. Cancer Cell 2007, 12:479-491.
7. Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD:
Normal human mammary epithelial cells spontaneously escape
senescence and acquire genomic changes. Nature 2001, 409:633-637.
8. Davalos AR, Coppe JP, Campisi J, Desprez PY: Senescent cells as a source
of inflammatory factors for tumor progression. Cancer Metastasis Rev
2010, 29:273-283.
9. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR,
Freund A, Campeau E, Davalos AR, Campisi J: Persistent DNA damage
signalling triggers senescence-associated inflammatory cytokine
secretion. Nature Cell Biol 2009, 11:973-979.
10. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401.
11. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR:
Carcinoma-associated fibroblasts direct tumor progression of initiated
human prostatic epithelium. Cancer Res 1999, 59:5002-5011.
12. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R,
Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in
invasive human breast carcinomas promote tumor growth and
angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005,
121:335-348.
13. Tlsty TD, Coussens LM: Tumor stroma and regulation of cancer
development. Annu Rev Pathol 2006, 1:119-150.
14. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-
Menezes D, Tsirigos A, Witkiewicz A, Lin Z, Balliet R, Howell A, Stogia F:
Understanding the “lethal” drivers of tumor-stroma co-evolution:
emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy
in the tumor micro-environment. Cancer Biol Ther 2010, 10:537-542.
15. Fiaschi T, Chiarugi P: Oxidative stress, tumor microenvironment, and
metabolic reprogramming: a diabolic liaison. Int J Cell Biol 2012,
2012:762-825.
16. Rasanen K, Vaheri A: Activation of fibroblasts in cancer stroma. Exp Cell
Res 2010, 316:2713-2722.
17. Dvorak HF, Weaver VM, Tlsty TD, Bergers G: Tumor microenvironment and
progression. J Surg Oncol 2011, 103:468-474.
18. Holst CR, Nuovo GJ, Esteller M, Chew K, Baylin SB, Herman JG, Tlsty TD:
Methylation of p16(INK4a) promoters occurs in vivo in histologically
normal human mammary epithelia. Cancer Res 2003, 63:1596-1601.
19. Hammond SL, Ham RG, Stampfer MR: Serum-free growth of human
mammary epithelial cells: rapid clonal growth in defined medium and
extended serial passage with pituitary extract. Proc Natl Acad Sci USA
1984, 81:5435-5439.
20. Heaphy CM, Subhawong AP, Gross AL, Konishi Y, Kouprina N, Argani P,
Visvanathan K, Meeker AK: Shorter telomeres in luminal B, HER-2 and
triple-negative breast cancer subtypes. Mod Pathol 2011, 24:194-200.
21. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N,
Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S,
Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP: The reverse
Warburg effect: aerobic glycolysis in cancer associated fibroblasts and
the tumor stroma. Cell Cycle 2009, 8:3984-4001.
22. Harris RE: Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer.
Subcell Biochem 2007, 42:93-126.
23. Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M, Thill M: Impact of
cyclooxygenase-2 in breast cancer. Anticancer Res 2011, 31:4359-4367.
24. Ferreira MC, Witz CA, Hammes LS, Kirma N, Petraglia F, Schenken RS,
Reis FM: Activin A increases invasiveness of endometrial cells in an in
vitro model of human peritoneum. Mol Hum Reprod 2008, 14:301-307.
25. Kang HY, Huang HY, Hsieh CY, Li CF, Shyr CR, Tsai MY, Chang C,
Chuang YC, Huang KE: Activin A enhances prostate cancer cell migration
through activation of androgen receptor and is overexpressed in
metastatic prostate cancer. J Bone Miner Res 2009, 24:1180-1193.
26. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A: COX-2
overexpression increases motility and invasion of breast cancer cells. Int
J Oncol 2005, 26:1393-1399.
27. Meeker AK, De Marzo AM: Recent advances in telomere biology:
implications for human cancer. Curr Opin Oncol 2004, 16:32-38.
28. O’Sullivan JN, Bronner MP, Brentnall TA, Finley JC, Shen WT, Emerson S,
Emond MJ, Gollahon KA, Moskovitz AH, Crispin DA, Potter JD,
Rabinovitch PS: Chromosomal instability in ulcerative colitis is related to
telomere shortening. Nat Genet 2002, 32:280-284.
29. Meeker AK, Argani P: Telomere shortening occurs early during breast
tumorigenesis: a cause of chromosome destabilization underlying
malignant transformation? J Mammary Gland Biol Neoplasia 2004,
9:285-296.
30. Fordyce CA, Heaphy CM, Bisoffi M, Wyaco JL, Joste NE, Mangalik A,
Baumgartner KB, Baumgartner RN, Hunt WC, Griffith JK: Telomere content
correlates with stage and prognosis in breast cancer. Breast Cancer Res
Treat 2006, 2:193-202.
31. Hansel DE, Meeker AK, Hicks J, De Marzo AM, Lillemoe KD, Schulick R,
Hruban RH, Maitra A, Argani P: Telomere length variation in biliary tract
metaplasia, dysplasia, and carcinoma. Mod Pathol 2006, 19:772-779.
32. Heaphy CM, Baumgartner KB, Bisoffi M, Baumgartner RN, Griffith JK:
Telomere DNA content predicts breast cancer-free survival interval. Clin
Cancer Res 2007, 13:7037-7043.
33. Rampazzo E, Bonaldi L, Trentin L, Visco C, Keppel S, Giunco S, Frezzato F,
Facco M, Novella E, Giaretta I, Del Bianco P, Semenzato G, De Rossi A:
Telomere length and telomerase levels delineate subgroups of B-cell
chronic lymphocytic leukemia with different biological characteristics
and clinical outcomes. Haematologica 2012, 97:56-63.
34. Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstatter A,
Kronenberg F, Kiechl S: Telomere length and risk of incident cancer and
cancer mortality. JAMA 2010, 304:69-75.
35. Chiavarina B, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A,
Tanowitz HB, Pestell RG, Sotgia F, Lisanti MP: Metabolic reprogramming
and two-compartment tumor metabolism: opposing role(s) of HIF1alpha
and HIF2alpha in tumor-associated fibroblasts and human breast cancer
cells. Cell Cycle 2012, 11:3280-3289.
36. Guido C, Whitaker-Menezes D, Capparelli C, Balliet R, Lin Z, Pestell RG,
Howell A, Aquila S, Andò S, Martinez-Outschoorn U, Sotgia F, Lisanti MP:
Metabolic reprogramming of cancer-associated fibroblasts by TGF-beta
drives tumor growth: connecting TGF-beta signaling with “Warburg-like”
cancer metabolism and L-lactate production. Cell Cycle 2012,
11:3019-3035.
37. Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Tanowitz HB,
Sotgia F, Lisanti MP: Stromal-epithelial metabolic coupling in cancer:
integrating autophagy and metabolism in the tumor microenvironment.
Int J Biochem Cell Biol 2011, 43:1045-1051.
38. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, Martinez-
Outschoorn UE, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP:
Warburg meets autophagy: cancer-associated fibroblasts accelerate
tumor growth and metastasis via oxidative stress, mitophagy, and
aerobic glycolysis. Antioxid Redox Signal 2012, 16:1264-1284.
Fordyce et al. Breast Cancer Research 2012, 14:R155
http://breast-cancer-research.com/content/14/6/R155
Page 17 of 18
39. Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I,
Tlsty TD, Esserman LJ: Cyclooxygenase-2 expression is related to nuclear
grade in ductal carcinoma in situ and is increased in its normal adjacent
epithelium. Cancer Res 2003, 63:2347-2350.
40. Rodier F, Campisi J: Four faces of cellular senescence. J Cell Biol 2011,
192:547-556.
41. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N,
Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H,
Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L,
Ørntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J,
Gorgoulis VG: Oncogene-induced senescence is part of the
tumorigenesis barrier imposed by DNA damage checkpoints. Nature
2006, 444:633-637.
42. Collado M, Blasco MA, Serrano M: Cellular senescence in cancer and
aging. Cell 2007, 130:223-233.
43. Shay JW, Roninson IB: Hallmarks of senescence in carcinogenesis and
cancer therapy. Oncogene 2004, 23:2919-2933.
44. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS,
Desprez PY, Campisi J: Senescence-associated secretory phenotypes
reveal cell-nonautonomous functions of oncogenic RAS and the p53
tumor suppressor. PLoS Biol 2008, 6:2853-2868.
45. Zdanov S, Bernard D, Debacq-Chainiaux F, Martien S, Gosselin K,
Vercamer C, Chelli F, Toussaint O, Abbadie C: Normal or stress-induced
fibroblast senescence involves COX-2 activity. Exp Cell Res 2007,
313:3046-3056.
46. Chen YG, Wang Q, Lin SL, Chang CD, Chuang J, Ying SY: Activin signaling
and its role in regulation of cell proliferation, apoptosis, and
carcinogenesis. Exp Biol Med (Maywood) 2006, 231:534-544.
47. Reis FM, Luisi S, Carneiro MM, Cobellis L, Federico M, Camargos AF,
Petraglia F: Activin, inhibin and the human breast. Mol Cell Endocrinol
2004, 225:77-82.
48. Krneta J, Kroll J, Alves F, Prahst C, Sananbenesi F, Dullin C, Kimmina S,
Phillips DJ, Augustin HG: Dissociation of angiogenesis and tumorigenesis
in follistatin- and activin-expressing tumors. Cancer Res 2006,
66:5686-5695.
49. Reis FM, Cobellis L, Tameirao LC, Anania G, Luisi S, Silva IS, Gioffre W, Di
Blasio AM, Petraglia F: Serum and tissue expression of activin a in
postmenopausal women with breast cancer. J Clin Endocrinol Metab 2002,
87:2277-2282.
50. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D,
Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P,
Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L,
Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B,
Kinzler KW, Velculescu VE: The consensus coding sequences of human
breast and colorectal cancers. Science 2006, 314:268-274.
51. Mylonas I, Jeschke U, Shabani N, Kuhn C, Friese K, Gerber B: Inhibin/activin
subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed
in human breast cancer and their metastasis. Oncol Rep 2005, 13:81-88.
52. Reinholz MM, Iturria SJ, Ingle JN, Roche PC: Differential gene expression of
TGF-beta family members and osteopontin in breast tumor tissue:
analysis by real-time quantitative PCR. Breast Cancer Res Treat 2002,
74:255-269.
53. Kim H, Watkinson J, Varadan V, Anastassiou D: Multi-cancer computational
analysis reveals invasion-associated variant of desmoplastic reaction
involving INHBA, THBS2 and COL11A1. BMC Med Genomics 2010, 3:51.
54. Robinson GW, Hennighausen L: Inhibins and activins regulate mammary
epithelial cell differentiation through mesenchymal-epithelial
interactions. Development 1997, 124:2701-2708.
55. Sobral LM, Bufalino A, Lopes MA, Graner E, Salo T, Coletta RD:
Myofibroblasts in the stroma of oral cancer promote tumorigenesis via
secretion of activin A. Oral Oncol 2011, 47:840-846.
56. Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, Di
Trapani D, Gebbia N, Leto G: MMP-2, MMP-9 and activin A blood levels in
patients with breast cancer or prostate cancer metastatic to the bone.
Anticancer Res 2007, 27:1519-1525.
57. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C,
Crescimanno M, Rini G: Activin A circulating levels in patients with bone
metastasis from breast or prostate cancer. Clin Exp Metastasis 2006,
23:117-122.
58. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT,
Wang ZC, Richardson AL, Weinberg RA, Orimo A: Autocrine TGF-beta and
stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of
tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci
USA 2010, 107:20009-20014.
59. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ: The origin of the
myofibroblasts in breast cancer: recapitulation of tumor environment in
culture unravels diversity and implicates converted fibroblasts and
recruited smooth muscle cells. J Clin Invest 1995, 95:859-873.
60. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M,
Marini F: Mesenchymal stem cell transition to tumor-associated
fibroblasts contributes to fibrovascular network expansion and tumor
progression. PLoS One 2009, 4:e4992.
61. Delli Carpini J, Karam AK, Montgomery L: Vascular endothelial growth
factor and its relationship to the prognosis and treatment of breast,
ovarian, and cervical cancer. Angiogenesis 2010, 13:43-58.
62. Singh B, Vincent L, Berry JA, Multani AS, Lucci A: Cyclooxygenase-2
expression induces genomic instability in MCF10A breast epithelial cells.
J Surg Res 2007, 140:220-226.
63. DeNardo DG, Johansson M, Coussens LM: Immune cells as mediators of
solid tumor metastasis. Cancer Metastasis Rev 2008, 27:11-18.
doi:10.1186/bcr3368
Cite this article as: Fordyce et al.: Cell-extrinsic consequences of
epithelial stress: activation of protumorigenic tissue phenotypes. Breast
Cancer Research 2012 14:R155.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Fordyce et al. Breast Cancer Research 2012, 14:R155
http://breast-cancer-research.com/content/14/6/R155
Page 18 of 18
